- Date: 25.09.2019
- Time: 16:30 am – 18:30 pm including snacks
- Location: Embassy of Switzerland, 77 Songwol-gil, Jongno-gu, Seoul
- Participants : limited to 15-20 by registration order
- Free of charge but registration compulsory
- Registration and info: firstname.lastname@example.org
This month speaker
Rajib Schubert, Ph.D.
Director of Innovation, Cellfebiotech, San Carlos, USA
Principle investigator and visiting scientist, Kyunghee University, Seoul, Korea
Rajib received his BSc and MSc from Columbia University in Biomedical Engineering and a PhD from ETH Zurich (Switzerland) Biophysics. He then went on for his postdoctoral studies at Caltech where he focused on developing targeted therapies using cell specific viruses. He held project positions at Roche Molecular systems (2005-2006) and Novartis Institute of Biomedical research, Basel, Switzerland (2011-2016) before taking up his current positions as a principle investigator at Kyunghee University, and at Cellbiotech, USA, as director of innovation. His research combines materials science and biochemical techniques to develop new tools and methods in targeted delivery of therapeutic molecules in cell therapy with a focus in the area of neuroscience and oncology.
Biodistribution and efficacy analyses of a targeted adenoviral therapy via CLARITY and deep imaging of intact tumors
Authors: Rajib Schubert1, Sheena N. Smith2, Junho Hur3, Viviana Gradinaru1 & Andreas Plückthun2 1California Institute of Technology, USA, 2University of Zürich, Switzerland, 3Kyung Hee University South Korea
Introduction: Cancer continues to be a major global health problem. This problem is in big part due to the administration of therapeutic agents that are highly effective, but toxic due to continuous high local concentrations for efficacy. To address this, we have engineered a novel gene therapy platform in which nonreplicative adenoviruses harboring the genes for secreted payload combinations are engineered to transduce tumor cells specifically and convert them into therapeutic-secreting biofactories. Using state-of-the-art whole tumor clearing and imaging we validate the biodistribution of this novel gene therapy vector and the payload it encodes.
Materials and Methods: HER2- retargeted, shielded adenovirus variants were engineered to encode a secreted therapeutic antibody against human HER2 (Ad-TZB) [1-3]. Human BT474 breast carcinoma xenografts (HER2+) were engrafted in the mammary fat pad of female SCID-beige mice (Figure 1A). Tumors were harvested 11-days and 61-days post the onset of treatment via perfusion-fixation for CLARITY[4-5] and confocal microscopy (Figure 1B).
Results and Discussion: We first validate the cell specific infection of our viruses in vivo using CLARITY based tissue clearing for high resolution and large volumetric imaging. We next validate several parameters of our gene delivery approach by assessing several therapeutic parameters such as vasculature, cell counts and biodistribution of our therapeutics using our CLARITY imaging assay. Our results confirm continuous intratumoral activity with an improved therapeutic index(Figure 1C).
Figure 1. CLARITY based imaging for assessing efficacy of adenovirus gene delivery platform. (A-B) Schematic showing our gene delivery work flow and assessment of tumors. (C) Quantification of vasculature (left) and cell density (right) change upon treatment, tumors from n=3 mice. Statistical significance was assessed by two-sided unpaired Welch’s t-test. NS, not significant; *P < 0.05, **P < 0.01, ***P < 0.001.
Conclusions: Our gene delivery approach and imaging assessment shows that we can individualize therapy by delivering complex combinations of biologics, using targeted viruses. Our results point to promising future studies to individualize therapy and limit systemic toxicity of drugs.
①Dreier, et al. (2013). Proc Natl Acad Sci USA 110, e8X69.
②Dreier, et al. (2011). J Mol Biol 405, 410.
③Schmid, et al. (2018). Nat Comm 9, 450.
④Yang, et al. (2014). Cell, 10, 1860.
⑤Chung, et al. (2013), Nature, 497, 332.